Nanoparticle-mediated delivery of a base editor for in utero treatment of Canavan Disease

纳米颗粒介导的碱基编辑器递送用于子宫内治疗卡纳万病

基本信息

  • 批准号:
    10727872
  • 负责人:
  • 金额:
    $ 42.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-06-01 至 2025-05-31
  • 项目状态:
    未结题

项目摘要

ABSTRACT Canavan disease is a rare genetic neurological disorder characterized by a vacuolar (spongiform) leukodystrophy caused by ASPA mutations that diminish brain aspartoacylase activity. Neonatal/infantile Canavan disease is the most common and most severe form of the condition. Affected infants appear normal for the first few months of life, but problems with development become noticeable by age 3 to 5 months. These infants usually do not develop motor skills such as turning over, controlling head movement, and sitting without support. Other characteristics of this condition include hypotonia, macrocephaly, and irritability. There is no cure, nor is there a standard course of treatment. The symptomatic support for this neurodegenerative disorder includes dietary manipulations, administration of lithium citrate and anticonvulsants, and AAV-mediated brain parenchymal ASPA gene therapy, yet, these treatments do not reverse or prevent the progression of neurological deficits in affected infants and children. To address this unmet medical need, we propose to develop an innovative treatment comprised of an in utero delivery of solid lipid nanoparticle (LNP)/mRNA complexes by intraventricular injection that will target and edit oligodendrocyte before birth, correct ASAP mutations, and restore aspartoacylase expression in patients influenced by point mutations. Gene editing at the in utero stage has great potential to cure neurological disorders, including Canavan disease before symptoms are unset. Our preliminary studies demonstrated that in utero intraventricular delivery LNP mRNA complexes can efficiently deliver mRNA to the brain and spinal cord tissue. These experiments are the first demonstration of mRNA based nonviral gene editing in utero and open up numerous therapeutic applications, given the tremendous versatility of mRNA. The central hypothesis of this proposal is that: LNPs will deliver mRNA for gene editing enzymes in utero and will rescue mice from Canavan disease at and after birth. This hypothesis is based upon our preliminary data demonstrating that LNPs containing CRE can safely and efficiently transfect oligodendrocyte in the brain of Ai9 mice after in utero intraventricular delivery. The central objective of this study is to develop LNP formulations that can efficiently edit oligodendrocyte in utero and develop a strategy for treating Canavan disease.
摘要 卡纳万病是一种罕见的遗传性神经系统疾病,其特征是空泡状(海绵状) 由ASPA突变引起的脑白质营养不良,该突变降低了脑乙酰化酶的活性。 新生儿/婴儿卡纳万病是最常见和最严重的形式的条件。 受影响的婴儿在出生后的头几个月看起来正常,但发育问题变得越来越严重。 在3到5个月大的时候就很明显了。这些婴儿通常不会发展运动技能,如翻身, 控制头部运动,无支撑地坐着。这种情况的其他特征包括 张力减退、大头畸形和易怒。没有治愈方法,也没有标准的治疗过程。 这种神经退行性疾病的症状支持包括饮食控制, 施用柠檬酸锂和抗惊厥剂,以及AAV介导的脑实质ASPA基因 然而,这些治疗并不能逆转或阻止神经功能缺损的进展, 影响婴儿和儿童。为了满足这一未得到满足的医疗需求,我们建议开发一种创新的 治疗,包括通过子宫内递送固体脂质纳米颗粒(LNP)/mRNA复合物, 脑室内注射将在出生前靶向和编辑少突胶质细胞,纠正ASAP突变, 并恢复受点突变影响的患者的乙酰化酶表达。最新的基因编辑 子宫期有很大的潜力治愈神经系统疾病,包括卡纳万病之前, 症状不明显。我们的初步研究表明,在子宫内脑室内输送LNP mRNA复合物可以有效地将mRNA递送到脑和脊髓组织。这些实验 是首次在子宫内展示基于mRNA的非病毒基因编辑, 考虑到mRNA的巨大多功能性,这个问题的核心假设是 提议是:LNP将在子宫内递送基因编辑酶的mRNA,并将拯救小鼠免受 出生时和出生后的Canavan病。这个假设是基于我们的初步数据, 含CRE的LNPs能安全、有效地抑制Ai 9小鼠脑内少突胶质细胞 在子宫内脑室内分娩后。本研究的中心目标是开发LNP制剂 它可以在子宫内有效地编辑少突胶质细胞,并开发出治疗卡纳万病的策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David E. Pleasure其他文献

Tissue culture analysis of neurogenesis: Myelination and synapse formation are retarded by serum deprivation
  • DOI:
    10.1016/0006-8993(78)90792-8
  • 发表时间:
    1978-04-21
  • 期刊:
  • 影响因子:
  • 作者:
    Seung U. Kim;David E. Pleasure
  • 通讯作者:
    David E. Pleasure

David E. Pleasure的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David E. Pleasure', 18)}}的其他基金

Manipulating N-acetyl-L-aspartate transport to treat Canavan leukodystrophy
操纵 N-乙酰基-L-天冬氨酸转运来治疗 Canavan 脑白质营养不良
  • 批准号:
    10406711
  • 财政年份:
    2022
  • 资助金额:
    $ 42.39万
  • 项目类别:
Manipulating N-acetyl-L-aspartate transport to treat Canavan leukodystrophy
操纵 N-乙酰基-L-天冬氨酸转运来治疗 Canavan 脑白质营养不良
  • 批准号:
    10554428
  • 财政年份:
    2022
  • 资助金额:
    $ 42.39万
  • 项目类别:
Manipulating N-acetyl-L-aspartate to reverse Canavan leukodystrophy
操纵 N-乙酰基-L-天冬氨酸逆转 Canavan 脑白质营养不良
  • 批准号:
    10026520
  • 财政年份:
    2020
  • 资助金额:
    $ 42.39万
  • 项目类别:
CANAVAN DISEASE: SUPPRESSING THE PHENOTYPE BY INHIBITING NAA SYNTHESIS
CANAVAN 病:通过抑制 NAA 合成来抑制表型
  • 批准号:
    8965565
  • 财政年份:
    2015
  • 资助金额:
    $ 42.39万
  • 项目类别:
CORE--CELLULAR NEUROSCIENCE CORE
核心--细胞神经科学核心
  • 批准号:
    7670394
  • 财政年份:
    2008
  • 资助金额:
    $ 42.39万
  • 项目类别:
IMPROVING THE ANIMAL FACILITY
改善动物设施
  • 批准号:
    6090027
  • 财政年份:
    2000
  • 资助金额:
    $ 42.39万
  • 项目类别:
CORE--CELL CULTURE AND BIOCHEMISTRY
核心--细胞培养和生物化学
  • 批准号:
    6204978
  • 财政年份:
    1999
  • 资助金额:
    $ 42.39万
  • 项目类别:
CORE--CELL CULTURE AND BIOCHEMISTRY
核心--细胞培养和生物化学
  • 批准号:
    6302705
  • 财政年份:
    1999
  • 资助金额:
    $ 42.39万
  • 项目类别:
CORE--CELLULAR NEUROSCIENCE CORE
核心--细胞神经科学核心
  • 批准号:
    6202079
  • 财政年份:
    1999
  • 资助金额:
    $ 42.39万
  • 项目类别:
CORE--CELLULAR NEUROSCIENCE CORE
核心--细胞神经科学核心
  • 批准号:
    6108562
  • 财政年份:
    1998
  • 资助金额:
    $ 42.39万
  • 项目类别:

相似海外基金

Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
  • 批准号:
    495182
  • 财政年份:
    2023
  • 资助金额:
    $ 42.39万
  • 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
  • 批准号:
    2601817
  • 财政年份:
    2021
  • 资助金额:
    $ 42.39万
  • 项目类别:
    Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
  • 批准号:
    2029039
  • 财政年份:
    2020
  • 资助金额:
    $ 42.39万
  • 项目类别:
    Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
  • 批准号:
    9888417
  • 财政年份:
    2019
  • 资助金额:
    $ 42.39万
  • 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
  • 批准号:
    17K11318
  • 财政年份:
    2017
  • 资助金额:
    $ 42.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9320090
  • 财政年份:
    2017
  • 资助金额:
    $ 42.39万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    10166936
  • 财政年份:
    2017
  • 资助金额:
    $ 42.39万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9761593
  • 财政年份:
    2017
  • 资助金额:
    $ 42.39万
  • 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
  • 批准号:
    BB/M50306X/1
  • 财政年份:
    2014
  • 资助金额:
    $ 42.39万
  • 项目类别:
    Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
  • 批准号:
    288272
  • 财政年份:
    2013
  • 资助金额:
    $ 42.39万
  • 项目类别:
    Miscellaneous Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了